Fused Tetracyclic Compounds for Hepatitis B Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B, such as interferon and nucleoside analogues, have limitations including low response rates, side effects, high costs, and the development of drug-resistant strains, necessitating the need for new antiviral compounds.
Innovation Solution
Development of novel fused tetracyclic compounds with good pharmacokinetic properties, low toxicity, and effective inhibitory activity against HBV infection, which can be used alone or in combination with other antiviral agents to treat and prevent hepatitis B.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon is used for HBV treatment, then viral clearance effect is achieved, but response rate is low and side effects occur
Solution Approach 1:
The invention segments the antiviral mechanism into two distinct components: (1) nucleoside analogue compounds that specifically inhibit viral DNA polymerase to block viral replication, and (2) adjuvant compounds that modulate immune response to enhance clearance of infected cells. This segmentation allows each component to perform its specialized function with optimized efficacy and reduced side effects compared to interferon monotherapy.
Solution Approach 2:
The invention creates a composite therapeutic regimen combining nucleoside analogue compounds (such as lamivudine, adefovir dipivoxil, entecavir, telbivudine, or tenofovir) with specific adjuvant compounds. This composite approach synergistically combines direct antiviral action with immune modulation, achieving improved viral clearance with a more favorable side effect profile than interferon alone.
2Reliability
If nucleoside analogues are used for HBV treatment, then viral replication is strongly inhibited, but drug-resistant strains emerge
Solution Approach 1:
The invention divides the antiviral strategy into two functional segments: nucleoside analogues that directly inhibit viral DNA polymerase and adjuvant compounds that enhance immune-mediated clearance of infected cells. This segmentation reduces selective pressure on the virus to develop resistance against nucleoside analogues alone, as the adjuvant component provides an additional clearance mechanism that is less prone to resistance development.
Solution Approach 2:
The composite therapeutic regimen combines nucleoside analogue compounds with adjuvant compounds that modulate immune response. This combination therapy creates multiple barriers to resistance: the nucleoside analogue provides direct antiviral activity while the adjuvant enhances immune clearance, making it harder for the virus to develop escape mutations. The synergistic interaction between the two components maintains stable antiviral efficacy over long-term treatment.
3Reliability
If interferon is used for HBV treatment, then viral clearance is achieved, but treatment cost is high
Solution Approach 1:
The invention replaces expensive interferon therapy with nucleoside analogue compounds that are significantly more cost-effective. These nucleoside analogues (lamivudine, adefovir dipivoxil, entecavir, telbivudine, tenofovir) are orally available, have long half-lives allowing once-daily dosing, and can be manufactured at lower cost. The addition of adjuvant compounds further enhances efficacy, making the overall regimen both affordable and effective.
Solution Approach 2:
The composite regimen of nucleoside analogues plus adjuvant compounds achieves viral clearance efficacy comparable to or better than interferon, but at a fraction of the cost. The nucleoside analogue component provides sustained antiviral activity with excellent cost-effectiveness, while the adjuvant component optimizes immune response, together delivering a high-value therapeutic solution that is accessible to broader patient populations.
4Reliability
If new antiviral compounds are developed, then treatment efficacy is improved, but pharmacokinetic properties and toxicity must be optimized
Solution Approach 1:
The invention optimizes the chemical structure of nucleoside analogue compounds by modifying parameters such as substituent groups at specific positions (R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n) to enhance antiviral activity while improving pharmacokinetic properties including solubility, metabolic stability, and oral bioavailability. These structural modifications also reduce toxicity by avoiding metabolic pathways that generate harmful intermediates.
Solution Approach 2:
The adjuvant compounds serve as intermediaries that modulate the immune system to enhance clearance of HBV-infected cells. By activating immune cells through specific receptors (such as Toll-like receptors or other pattern recognition receptors), the adjuvants amplify the body's natural antiviral defenses, allowing lower doses of nucleoside analogues to be used and thereby reducing their potential toxicity while maintaining or enhancing overall antiviral efficacy.
Data Source
AI summary
A fused tetracyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. A compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B, wherein each variable is as defined in the specification.